Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Genetic matters of CYP2D6 in breast cancer: copy number variations and nucleotide polymorphisms

Nature Reviews Cancer volume 9, pages 842–843 (2009)Cite this article

Access through your institution
Buy or subscribe

We read with great interest the content-rich Review CYP2D6 and tamoxifen: DNA matters in breast cancer (Nature Rev. Cancer 9, 576–586 (2009)) by Hoskins et al.1, which presents the current knowledge on CYP2D6 and tamoxifen in breast cancer. It is thought that CYP2D6 polymorphisms affect CYP2D6 enzyme activity, which further influences the metabolism of tamoxifen as well as the outcome of tamoxifen therapy. The authors concluded that genotype-guided tamoxifen administration might be useful as part of a strategy to optimize the treatment of breast cancer. However, there are two important questions that relate to the CYP2D6 genotype in current research. First, as the authors critically discussed, most studies have not genotyped other non-synonymous alleles except for the CYP2D6*4 allele in the polymorphic CYP2D6 gene2,3,4. Second, CYP2D6 copy number variations (CNVs) have not been fully considered. In this correspondence, we wish to draw attention to this important area of research on CYP2D6.

Genomic variability is present in many forms, including single nucleotide polymorphisms (SNPs), variable numbers of tandem repeats, copy number alterations and so on5. SNPs were previously thought to be the predominant form of genomic variation and to account for most phenotypic variation. More recently, CNVs have been identified and investigated in normal individuals. CYP2D6 is known to be an important tamoxifen-metabolizing gene that is subject to genetic deletion, duplication and multiplication, resulting in varying enzyme activity6. Here, we define 'nucleotide polymorphism' as a term representing genetic variation that includes insertion, deletion and replacement of one nucleotide or several nucleotides in CYP2D6. CNV represents a copy number change involving a DNA fragment ≥1 kb. Although the understanding of CNVs is still evolving, it is acknowledged that CNVs result in differential gene expression and account for a substantial proportion of phenotypic variation. For CYP2D6, three or four or more copies have been identified7 (Table 1). Moreover, CYP2D6 CNV occurs at a high frequency in some populations (Table 2), indicating that the effect of CNVs on CYP2D6 expression is unlikely to be negligible in these populations. Therefore, we propose that, like genotyping CYP2D6 nucleotide polymorphisms, the determination of CNVs should be evaluated, at least in some populations.

Table 1 The copy number changes of CYP2D6 according to the allele numbers
Full size table
Table 2 The frequency of CYP2D6 gene copy number variations
Full size table

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hoskins, J. M., Carey, L. A. & McLeod, H. L. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nature Rev. Cancer 9, 576–586 (2009).

    CAS  PubMed  Google Scholar 

  2. Schroth, W. et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25, 5187–5193 (2007).

    CAS  Google Scholar 

  3. Goetz, M. P. et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101, 113–121 (2007).

    CAS  Google Scholar 

  4. Gjerde, J. et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann. Oncol. 19, 56–61 (2008).

    CAS  Google Scholar 

  5. Freeman, J. L. et al. Copy number variation: new insights in genome diversity. Genome Res. 16, 949–961 (2006).

    CAS  Google Scholar 

  6. Meijerman, I., Sanderson, L. M., Smits, P. H., Beijnen, J. H. & Schellens, J. H. Pharmacogenetic screening of the gene deletion and duplications of CYP2D6. Drug Metab. Rev. 39, 45–60 (2007).

    CAS  Google Scholar 

  7. Ingelman-Sundberg, M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5, 6–13 (2005).

    CAS  Google Scholar 

  8. Bodin, L., Beaune, P. H. & Loriot, M. A. Determination of cytochrome P450 2D6 (CYP2D6) gene copy number by real-time quantitative PCR. J. Biomed. Biotechnol. 2005, 248–253 (2005).

    Google Scholar 

  9. Schaeffeler, E., Schwab, M., Eichelbaum, M. & Zanger, U. M. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum. Mutat. 22, 476–85 (2003).

    Article  CAS  Google Scholar 

  10. Toscano, C. et al. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenet. Genomics 16, 755–766 (2006).

    Article  CAS  Google Scholar 

  11. Rau, T., Diepenbruck, S., Diepenbruck, I. & Eschenhagen, T. The 2988G>A polymorphism affects splicing of a CYP2982D6 minigene. Clin. Pharmacol. Ther. 80, 555–558; author reply 558–560 (2006).

    CAS  Google Scholar 

  12. Bradford, L. D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3, 229–243 (2002).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ke-Da Yu and Zhi-Ming Shao are at the Breast Cancer Institute, Cancer Hospital, Shanghai Medical College, Fudan University, 200032, Shanghai, P.R. China

    Ke-Da Yu & Zhi-Ming Shao

Authors
  1. Ke-Da Yu
    View author publications

    Search author on:PubMed Google Scholar

  2. Zhi-Ming Shao
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Zhi-Ming Shao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, KD., Shao, ZM. Genetic matters of CYP2D6 in breast cancer: copy number variations and nucleotide polymorphisms. Nat Rev Cancer 9, 842–843 (2009). https://doi.org/10.1038/nrc2683-c1

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrc2683-c1

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing